The HLA class III subregion is responsible for an increased breast cancer risk

被引:40
作者
de Jong, MM
Nolte, IM
de Vries, EGE
Schaapveld, M
Kleibeuker, JH
Oosterom, E
Oosterwijk, JC
van der Hout, AH
van der Steege, G
Bruinenberg, M
Boezen, HM
Meerman, GJT
van der Graaf, WTA
机构
[1] Univ Groningen, Med Ctr, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Med Ctr, Dept Med Genet, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen, Med Ctr, Dept Gastroenterol, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen, Med Ctr, Dept Med Biol, NL-9700 RB Groningen, Netherlands
[5] Univ Groningen, Med Ctr, Dept Epidemiol, NL-9700 RB Groningen, Netherlands
[6] Comprehens Canc Ctr No Netherlands, Groningen, Netherlands
关键词
D O I
10.1093/hmg/ddg245
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BRCA1 and BRCA2 germline mutations account for <5% of breast cancer cases. Less penetrant breast cancer susceptibility genes are likely to exist. Earlier studies have suggested involvement of the HLA region. The HLA region was genotyped with 24 microsatellite markers and markers for two single nucleotide polymorphisms (SNPs) in TNFalpha and TNFbeta, in germline DNA from 956 breast cancer patients and 1271 family-based controls. Association analyses and the haplotype sharing statistic (HSS) were used to search for differences in haplotype sharing between patients and controls. Based on criteria known to influence genetic breast cancer risk, patients were divided into groups of high, moderate and low risk. The HSS revealed a significant difference in mean haplotype sharing between patients and controls for four consecutive markers (D6S2671, TNFa, D6S2672 and MICA), the highest being at D6S2671 (P = 0.017). Subgroup analyses showed that moderate-risk patients were responsible for this difference, with the strongest association for D6S2672 (P = 0.0009). A single haplotype was more frequent and longer in moderate-risk patients than in controls. The results were confirmed with association analyses. Individuals homozygous for haplotype 110-184 (D6S2672-MICA) were observed in 9.0% of moderate-risk patients and 1.5% of controls [odds ratio (OR)= 7.14], while heterozygotes were at a lower risk (OR = 1.41), suggesting a recessive effect. No association was observed between the two SNPs in TNFalpha (-308) and TNFbeta (intron 1) and breast cancer risk. The results reveal a potential role of the HLA class III subregion in susceptibility to breast cancer in patients at moderate familial risk.
引用
收藏
页码:2311 / 2319
页数:9
相关论文
共 41 条
[1]  
Abrahamova J, 1988, Acta Univ Carol Med Monogr, V123, P1
[2]   A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Stratton, MR ;
Peto, J ;
Ponder, BJ ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2002, 86 (01) :76-83
[3]   Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Ponder, BAJ ;
Easton, D .
GENETIC EPIDEMIOLOGY, 2001, 21 (01) :1-18
[4]   Heterogeneity in breast cancer and the problem of relevance of findings [J].
Aubele, M ;
Werner, M .
ANALYTICAL CELLULAR PATHOLOGY, 1999, 19 (02) :53-58
[5]  
Beck J, 2001, SOURCE-NOTE HIST ART, V21, P1
[6]   Complete sequence and gene map of a human major histocompatibility complex [J].
Beck, S ;
Geraghty, D ;
Inoko, H ;
Rowen, L ;
Aguado, B ;
Bahram, S ;
Campbell, RD ;
Forbes, SA ;
Guillaudeux, T ;
Hood, L ;
Horton, R ;
Janer, M ;
Jasoni, C ;
Madan, A ;
Milne, S ;
Neville, M ;
Oka, A ;
Qin, S ;
Ribas-Despuig, G ;
Rogers, J ;
Shiina, T ;
Spies, T ;
Tamiya, G ;
Tashiro, H ;
Trowsdale, J ;
Vu, Q ;
Williams, L ;
Yamazaki, M .
NATURE, 1999, 401 (6756) :921-923
[7]  
Biswal B M, 1998, Indian J Med Sci, V52, P177
[8]  
Boon M, 2001, NEUROGENETICS, V3, P221
[9]   POSITIVE CORRELATION BETWEEN BREAST-CANCER INCIDENCE AND HLA ANTIGENS [J].
BOUILLENNE, C ;
DENEUFBOURG, JM .
ONCOLOGY, 1979, 36 (04) :156-159
[10]   SEROLOGICAL AND MOLECULAR STUDY ON THE HLA PHENOTYPE OF FEMALE BREAST-CANCER PATIENTS [J].
CASOLI, C ;
ZANELLI, P ;
ADORNI, A ;
STARCICH, BR ;
NERI, T .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1207-1208